A 27 month study about a new Novartis drug has revealed that the chances of morbidity due to heart failure can be reduced by 20% and for other reasons by 16% as compared to the older drugs. The drug also reduced the risk of hospitalization due to cardiac failure by more than 21%.
The study has been dubbed as one of the biggest advances made against cardiac failure in more than a decade. It is first of its kind of experimental drug which lowers the morbidity as well as hospitalization due to cardiac failure by 20 percent. The drug by Novartis does not have a name but is already being hailed by doctors as revolutionary and can change the care of more than 50% of 6 million Americans and over 24 million people worldwide with heart failure.
Dr. Clyde Yancy, cardiology chief at Northwestern University in Chicago and a former American Heart Association president said, “This is a new day for patients. It’s been at least a decade since we’ve had a breakthrough of this magnitude,”
The study involved more than 8500 persons in 47 countries and was also one of the largest experiments ever conducted on cardiac failure. The study was paid as well as partly run by Novartis and is based in Basel Switzerland. The study was stopped seven months earlier than planned after it was amply clear that the drug was better than older one which is now the standard treatment for heart ailments.
The Results of the study were disclosed on Saturday at a European Society of Cardiology conference in Barcelona. The study was published online by the New England Journal of Medicine. Novartis will seek approval for the drug — for now called LCZ696 — by the end of this year in the United States and early next year in Europe
There are skeptics of the study who contend that Novartis may be pushing the study because the common drugs like Enalapril or Ramipril is available as generic drugs and therefore is no more profitable. However all these are just opinions and there are no proof of any such thing. Diverging opinions are common for any study and this study is no exception.